Stockreport
Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” [Yahoo! Finance]
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.amgen.com
With Amgen, I don't know if you remember, at the JPMorgan Healthcare Conference, I heard a lot of good things. The biotech really impressed me with a very strong pipeline. That, plus good earnings, and maybe some good news about this weight loss drug, could send this Dow stock higher. Photo by Artem Podrez on Pexels Amgen Inc. (NASDAQ:AMGN) delivers human therapeutics for conditions such as cancer, cardiovascular disease, osteoporosis, and autoimmune disorders. Cramer highlighted the company's cholesterol drug during the November 12, 2025, episode and said: We had Amgen on the show the other day, announcing a breakthrough in Repatha, its every other week injection squelches cholesterol to a level where it helps prevent heart attacks. Why not go buy that? While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands t
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | AMGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
AMGN alerts
AMGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
NEWS
NEWS
- CVS Health to swap Amgen and Lilly's bone drugs with biosimilars in commercial formularies [Seeking Alpha][Seeking Alpha]
- Oncology Biosimilars Research and Global Forecast Report 2025-2030: Targeted Therapies, Emerging Market Expansion, and Novel Biosimilar Formulations Drive Growth [Yahoo! Finance][Yahoo! Finance]
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Cantor Fitzgerald from $315.00 to $350.00. They now have a "neutral" rating on the stock.[MarketBeat]
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $403.00 to $415.00. They now have a "buy" rating on the stock.[MarketBeat]
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Morgan Stanley from $304.00 to $309.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- More
AMGN
SEC Filings
SEC Filings
- 2/3/26 - Form 8-K
- 1/30/26 - Form 8-K
- 11/21/25 - Form 4
- AMGN's page on the SEC website
- More